Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical ...
Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety Profile
Ähnliche Seiten
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting/2349722Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 | The Manila Times
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/autolus-therapeutics-to-present-clinical-data-update-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349713Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting...
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/crescent-biopharma-announces-trial-in-progress-presentation-for-ascend-study-of-cr-001-a-pd-1-x-vegf-bispecific-antibody-at-upcoming-american-society-of-clinical-oncology-asco-2026-annual-meeting/2349723Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting |...
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/rgenta-therapeutics-presents-positive-preliminary-data-from-ongoing-phase-1ab-clinical-trial-of-rgt-61159-in-patients-with-adenoid-cystic-carcinoma-and-colorectal-cancer-at-the-2026-asco-meeting/2349695Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa | The Manila Times
https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/infex-therapeutics-announces-positive-phase-iia-results-for-resp-x-in-non-cystic-fibrosis-bronchiectasis-patients-colonised-with-pseudomonas-aeruginosa/2348851